search twitter-square facebook-square linkedin-square google-plus-square bars navigate_next

FAQ's

Q: How is Creso placed in comparison to peers?
A: Creso has several points of difference to many of its ASX-listed peers:
  • It is the only company developing treatments for both animal and human health.
  • It is the only ASX-listed medical cannabis company backed by a Board and management team with a strong track record in both the pharma industry and the medical cannabis field.
  • It is the only company that is aiming for a broad patient reach through the nutraceutical market in addition to the medical cannabis market. Creso's nutraceutical products will be sold over the counter, thus avoiding the need for doctor's prescription.
  • It has international collaboration agreements with key players in North America and in Europe.
  • It has early access to emerging Israeli cannabis research, technologies and patents.

Creso is also one of a handful of listed companies that:

  • Is developing high quality products to GMP standards.
  • Is developing therapeutic products with standardised dose and formulation.
  • Is developing products using natural botanical full-plant extracts and non-synthetic materials (benefitting from the “entourage effect” and synergy of all the compounds in the plant); and
  • Has proprietary delivery technologies enhancing bioavailability and absorption.
Q: How is Creso different to other medical cannabis companies?
A: Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products. It is a leader in cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade medical cannabis and nutraceutical products with wide patient reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality, with initial product registrations in Switzerland. It also has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. The Company is already generating revenues via is subsidiary, Hemp-Industries.
Q: What is Creso's corporate structure?
A: Creso Pharma Limited wholly owns two entities: Creso Pharma Switzerland and Hemp-Industries Slovakia.
  • Creso Pharma Switzerland, based in Zug (Switzerland), is the legal entity that runs the Company’s operations and activities, specifically those situated in Europe being the development and commercialisation of its cannabis- and hemp-based therapeutic products for animal and human health.
  • Hemp-Industries is located in Slovakia and grows organic hemp for extraction in Germany to make CBD for its flagship product line 'CBDium'. Creso Pharma Limited has a distribution agreement with Hemp-Industries for the CBDium (hemp extract oil) product and is generating early revenues from that agreement. The 3% and 5% CBD bottles are sold via a Czech distributor in Central Europe. Additional products, such as hemp protein, are currently being sold to the food industry. Hemp-Industries is run by two executives, Michal Masek and Roman Sterchaj and the Board is augmented by Creso Pharma’s Executive Chairman and Co-Founder, Boaz Wachtel and Non-Executive Director & Co-Founder, Adam Blumenthal.
Q: What products are Creso bringing to market?
A: Creso has two distinct product lines: the products developed in Creso Switzerland for human and animal health, and the products from its subsidiary company, Hemp-Industries Slovakia as mentioned above.

Creso Switzerland is developing two human products based on the Swiss INNUtri proprietary delivery technology of starch-based SoftGums. The products are not swallowed tablets or capsules that go through the digestive system (GI tract). Rather, Creso’s delivery system delivers the cannabinoid molecules via buccal absorption through the mouth, enabling the molecules to go directly into the bloodstream and not be impacted by the stomach’s acids. This increases the absorption of the phytocannabinoid molecules and maximises the delivery of the molecules and their therapeutic effect. The products will be developed to the highest GMP quality standard for the development and manufacturing and will be registered in Switzerland as a reference product registration country.

The products will be developed to the highest GMP quality standard for the development and manufacturing and will be registered in Switzerland as a reference product registration country.

Q: What is unique about Creso's delivery technologies?
A: Creso has exclusive worldwide use of a number of delivery technologies for cannabis treatments through licensing deals with pharmaceutical companies. The first products will be based on the technology of INNUTRIGEL. The INNutri Soft GumsTM are innovative soft gums made of starch and not from the animal waste material gelatin like other gums. The technology uses buccal absorption of the cannabis molecules, enabling the molecules to go directly into the bloodstream via the mouth, increasing the absorption and maximising the delivery of the molecules and their therapeutic effect.
Q: When did Creso Pharma float on the ASX?
A: Creso listed on the ASX on October 20, 2016, having raised A$5 million.